GlobeNewsWire
17 Jun 2026, 05:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Kuros Biosciences is expanding the market application of MagnetOs into the trauma market, adding to its existing presence in spine, foot, and ankle. — Entry into a new therapeutic market (trauma) expands the total addressable market and potential revenue streams.
+0.50Kuros Biosciences will host a Capital Markets Day on June 17, 2026, to present its long-term value creation plan and commercial scaling strategy. — Investor days often serve as catalysts for price movement if the company provides updated guidance or aggressive growth targets.
+0.20A Level I human clinical study showed MagnetOs achieved a 79% fusion rate compared to 47% for autografts in posterolateral fusions. — Strong clinical efficacy data supports product adoption and competitive positioning against standard-of-care treatments.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is announcing a Capital Markets Day to showcase commercial momentum and growth plans for its MagnetOs product.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Accesswire
2h ago
